Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Receives $25.60 Consensus Target Price from Analysts

Shares of Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM – Get Free Report) have earned an average rating of “Buy” from the six brokerages that are presently covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have covered the stock […]

Related Keywords

,Cantor Fitzgerald ,Creative Financial Designs Inc ,Hedge Funds Weigh In On Actinium Pharmaceuticals ,Analyst Recommendations For Actinium Pharmaceuticals ,Vanguard Group Inc ,Actinium Pharmaceuticals ,Brandywine Global Investment Management ,Actinium Pharmaceuticals Stock Performance ,Actinium Pharmaceuticals Company Profile ,Virtu Financial ,News Ratings For Actinium Pharmaceuticals Daily ,Actinium Pharmaceuticals Inc ,Sanders Morris Harris ,Maxim Group ,Get Free Report ,Marketbeat Ratings ,Global Investment Management ,Financial Designs ,Get Free ,Actinium Pharmaceuticals Daily ,